Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
On November 14, BrightGene Bio-Medical Technology (688166) announced that the company plans to invest 50 million yuan in Suzhou Geek Gene Technology Co., Ltd. ("Geek Gene"), subscribing for an additional registered capital of 437,100 yuan in Geek Gene, with the remaining amount credited to the capital reserve fund of the target company. Prior to this investment, the company held 4.0816% equity in Geek Gene; after the investment, it will hold 12.8015% equity in the target company.Pharmaceutical Leader CQP: Plans to Acquire Shares in a Cell Therapy Development Company）
CQP stated that this investment is conducive to fully leveraging the strengths of both parties in innovative drug research and development and cell therapy technology, aligning with the company's innovation-driven development strategy. Suzhou Geek Gene Technology Co., Ltd. possesses unique technical expertise and advantages in areas such as cell fate reprogramming and low-cost, high-throughput omics technologies, helping the company to proactively position itself in cutting-edge fields of innovation, with potential synergies for the company’s product development.Suzhou Geek Gene Technology Co., Ltd. is an innovative cell drug development company characterized by the regulation of cell fate through high-throughput omics data, mainly engaged in single-cell sequencing services and immune cell therapy development.Currently focusing on developing long-lived tumor-reactive T-cell drugs for the treatment of mid- to late-stage solid tumors.。Suzhou Geek Gene Technology Co., Ltd. owns world-leading single-cell multi-omics data collection platforms, low-cost high-throughput omics technology platforms, and cell fate reprogramming technology platforms, with the stability of related data ranking at the forefront globally. Based on these three technological platforms, Suzhou Geek Gene has developed a cell fate navigation system, which is used to research and develop innovative T-cell therapeutic drugs.Suzhou Geek Gene Technology Co., Ltd.GK01 Cell Injection, a Class 1 new drug for advanced malignant solid tumors, has been approved for clinical trials in China. This drug is an innovative therapy based on autologous tumor-infiltrating lymphocytes (TIL). The core process involves isolating infiltrating T cells from the patient's tumor tissue and then optimizing them in vitro using Suzhou Geek Gene Technology Co., Ltd.'s proprietary cell fate reprogramming technology. This technology significantly enhances the precision of T-cell tumor recognition and cytotoxic activity, enabling the modified T cells to accurately target and attack tumor cells, offering a new treatment option for patients with advanced solid tumors.
Reference: Company Announcement
Mastering CAR-T Therapy, Stem Cell Therapy, Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
